CJC-1295 No DAC / Ipamorelin Mix.
About CJC-1295 No DAC / Ipamorelin Mix
CJC-1295 No DAC / Ipamorelin Mix is among the peptides researched in the context of the growth hormone (GH) axis. CJC-1295 activates the GHRH receptor while ipamorelin acts via the ghrelin receptor — two parallel signaling pathways within the same pituitary axis.
Research Application
Studied as a combination of two independent growth-hormone-axis pathways — the GHRH receptor (CJC-1295) and the ghrelin receptor (ipamorelin). No dedicated combination study exists; the synergy assumption rests on separate research into related compound classes.
Important to know
Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.
Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.
Research Overview
Numerous preclinical and some clinical studies exist on the GH axis, with evidentiary strength varying by substance.
- Teichman SL, et al. J Clin Endocrinol Metab. 2006;91(3):799–805. PMID 16352683
- Raun K, et al. Eur J Endocrinol. 1998;139(5):552–561. PMID 9849822
References without a PMID can be located via the respective publisher. This overview does not claim to be exhaustive.
Question about CJC-1295 No DAC / Ipamorelin Mix?
We reply personally – via email or Telegram.